Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC13424 LY2874455

    LY 2874455; LY-2874455

     A pan-FGFR inhibitor LY2874455 Chemical Structure
  3. GC40865 LYG-202 LYG-202 is a synthetic flavonoid with anticancer and anti-angiogenic activities. LYG-202 Chemical Structure
  4. GC69418 Lyn-IN-1

    Bafetinib analog

    Lyn-IN-1 (Bafetinib analog) is a highly active dual inhibitor of Bcr-Abl and Lyn.

     Lyn-IN-1 Chemical Structure
  5. GC62314 M4205 M4205 is a c-KIT inhibitor, with an IC50 of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17. M4205 Chemical Structure
  6. GC68304 Margetuximab Margetuximab Chemical Structure
  7. GC13410 Masitinib (AB1010)

    AB-1010, Masican, Masiviera

     Masitinib (AB1010) (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib (AB1010) Chemical Structure
  8. GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib mesylate Chemical Structure
  9. GC69436 Matuzumab

    EMD 72000

    Matuzumab (EMD 72000) is a humanized monoclonal antibody that can block EGFR activation and downstream signaling, inhibiting tumor growth.

     Matuzumab Chemical Structure
  10. GC66349 Mavrilimumab

    CAM 3001

     Mavrilimumab (CAM 3001) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. GM-CSF might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. Mavrilimumab Chemical Structure
  11. GC65179 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 Chemical Structure
  12. GC64583 MAX-40279 hemiadipate MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate Chemical Structure
  13. GC64582 MAX-40279 hemifumarate MAX-40279 hemifumarate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemifumarate Chemical Structure
  14. GC16483 MAZ51 VEGFR3 antagonist MAZ51 Chemical Structure
  15. GC64710 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate. MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Chemical Structure
  16. GC69460 Mefatinib

    Mifanertinib dimaleate

    Mefatinib is an effective tyrosine kinase inhibitor with anti-tumor activity.

     Mefatinib Chemical Structure
  17. GC69459 Mefatinib free base

    Mifanertinib

    Mefatinib free base is an effective tyrosine kinase inhibitor with anti-tumor activity.

     Mefatinib free base Chemical Structure
  18. GC14951 Meleagrin

    6-O-Methyloxaline

     antibiotic Meleagrin Chemical Structure
  19. GC36585 Merestinib dihydrochloride Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM). Merestinib dihydrochloride Chemical Structure
  20. GC68018 MET kinase-IN-2 MET kinase-IN-2 Chemical Structure
  21. GC12069 Methyl 2,5-dihydroxycinnamate

    Methyl 2,5dihydoxycinnamate

     EGF receptor-associated tyrosine kinases inhibitor Methyl 2,5-dihydroxycinnamate Chemical Structure
  22. GC36596 Methylnissolin

    (–)-Methylnissolin

     Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10 μM. Methylnissolin Chemical Structure
  23. GC13598 MGCD-265 MGCD-265 is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 has significant antitumor activity. MGCD-265 Chemical Structure
  24. GC61516 MID-1 MID-1 is a disruptor of MG53-IRS-1 (Mitsugumin 53-insulin receptor substrate-1) interaction. MID-1 Chemical Structure
  25. GC32819 Mirk-IN-1 (Dyrk1B/A-IN-1)

    Dyrk1B/A-IN-1

     Mirk-IN-1 (Dyrk1B/A-IN-1) is a potent inhibitor of Dyrk1B(Mirk kianse) and Dyrk1A with IC50 of 68±48 nM and 22±8 nM respectively. Mirk-IN-1 (Dyrk1B/A-IN-1) Chemical Structure
  26. GC16337 MK-2461 C-Met (WT/mutants) inhibitor MK-2461 Chemical Structure
  27. GC13140 MK-8033

    MK 8033;MK8033

     MK-8033 Chemical Structure
  28. GC36625 MK-8033 hydrochloride MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs). MK-8033 hydrochloride Chemical Structure
  29. GC47687 ML-209 An RORγt antagonist ML-209 Chemical Structure
  30. GC17582 ML347

    LDN193719

     BMP receptor inhibitor,potent and selective ML347 Chemical Structure
  31. GC30769 MLi-2 An LRRK2 inhibitor MLi-2 Chemical Structure
  32. GC10775 MLR 1023

    CP 26,154, NSC 314335

     MLR 1023 is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM. MLR 1023 Chemical Structure
  33. GC10048 MNS

    3,4Methylenedioxyβnitrostyrene, NSC 10120, NSC 105303, NSC 170724, Syk Inhibitor III

     Inhibitor of Src/Syk tyrosine kinases MNS Chemical Structure
  34. GC47697 Mobocertinib

    AP32788, TAK-788

     An inhibitor of mutant EGFR and HER2 receptors Mobocertinib Chemical Structure
  35. GC62160 Mobocertinib succinate Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research. Mobocertinib succinate Chemical Structure
  36. GC13012 Motesanib Motesanib Chemical Structure
  37. GC11336 Motesanib Diphosphate (AMG-706)

    Motesanib

     Motesanib Diphosphate (AMG-706) (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret. Motesanib Diphosphate (AMG-706) Chemical Structure
  38. GC69496 MRL-871

    MRL-871 (compound 3) is an effective inverse agonist of retinoic acid receptor-related orphan receptor gamma t (RORγt), with an IC50 of 264 nM. MRL-871 has a unique imidazole chemical structure and can effectively reduce the generation of IL-17a mRNA in EL4 cells.

     MRL-871 Chemical Structure
  39. GC13525 MRS 4062 triethylammonium salt P2Y4 receptor agonist MRS 4062 triethylammonium salt Chemical Structure
  40. GC32769 MRX-2843 (UNC2371)

    UNC2371

     MRX-2843 (UNC2371) (UNC2371) is an orally active, ATP-competitive dual MERTK and FLT3 tyrosine kinases inhibitor (TKI) with enzymatic IC50s of 1.3 nM for MERTK and 0.64 nM for FLT3, respectively. MRX-2843 (UNC2371) Chemical Structure
  41. GC65243 MS4077 MS4077 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 37?nM for binding affinity to ALK. MS4077 Chemical Structure
  42. GC64966 MS4078 MS4078 is an anaplastic lymphoma kinase (ALK) PROTAC (degrader) based on Cereblon ligand, with a Kd of 19?nM for binding affinity to ALK. MS4078 Chemical Structure
  43. GC15936 MSDC-0160

    Mitoglitazone; CAY10415

     mTOT-modulating insulin sensitizer MSDC-0160 Chemical Structure
  44. GC64431 MSDC-0602K

    Azemiglitazone potassium

     MSDC-0602K (Azemiglitazone potassium), a PPARγ-sparing thiazolidinedione (Ps-TZD), binds to PPARγ with the IC50 of 18.25 μM. MSDC-0602K Chemical Structure
  45. GC19256 MTX-211

    Mol 211

     MTX-211 is a dual inhibitor of EGFR and PI3K, used for the treatment of cancer and other diseases. MTX-211 Chemical Structure
  46. GC10250 Mubritinib (TAK 165)

    TAK-165

     Mubritinib (TAK 165) (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM. Mubritinib (TAK 165) Chemical Structure
  47. GC11126 Mutant EGFR inhibitor Selective Mutated EGFR inhibitor Mutant EGFR inhibitor Chemical Structure
  48. GC36666 Mutated EGFR-IN-1 Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant. Mutated EGFR-IN-1 Chemical Structure
  49. GC36667 Mutated EGFR-IN-2 Mutated EGFR-IN-2 (compound 91) is a mutant-selective EGFR inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=＜1nM) and ex19del/T790M), and can suppress activity of single gain-of-function mutant EGFR (including L858R and ex19del) as well. Mutated EGFR-IN-2 shows anti-tumor antivity. Mutated EGFR-IN-2 Chemical Structure
  50. GC44263 Myrtillin

    Delphinidin-3-β-D-glucoside chloride, Delphinidin-3-O-glucoside, Delphinin

     Myrtillin (Delphinidin 3-o-glucoside) is a kind of anthocyanin monomer, which is mainly distributed in various plants and can be analyzed qualitatively and quantitatively by high performance liquid chromatography (HPLC) Mass spectrometry (Mass) and nuclear magnetic resonance (NMR)

    Myrtillin at 50 uM does not affect cell viability, also showing that delphinidin in association with lipopolysaccharide was able to induce MSC proliferation. Myrtillin Chemical Structure

  51. GC40567 N-(p-Coumaroyl) Serotonin

    NSC 369503

     N-(p-Coumaroyl) serotonin is an antioxidative phenolic naturally found in plants, including safflower seed and millet grain. N-(p-Coumaroyl) Serotonin Chemical Structure
  52. GC70279 N-Acetyl-5-hydroxytryptamine-d3 N-Acetyl-5-hydroxytryptamine-d3 is the deuterium labeled N-Acetyl-5-hydroxytryptamine. N-Acetyl-5-hydroxytryptamine-d3 Chemical Structure
  53. GC11526 N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide Phosphopeptide for binding to the src SH2 domain N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide Chemical Structure
  54. GC12746 N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu Phosphopeptide ligand for the src SH2 domain N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu Chemical Structure
  55. GC15365 N-Acetylserotonin

    N-Acetyl-5-hydroxytryptamine,NAS

     N-Acetylserotonin is a Melatonin precursor, and that it can potently activate TrkB receptor. N-Acetylserotonin Chemical Structure
  56. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide Chemical Structure
  57. GC44290 NAADP (sodium salt)

    Nicotinic acid adenine dinucleotide phosphate

    Nicotinic acid adenine dinucleotide phosphate (NAADP) is a secondary messenger that induces calcium mobilization.

     NAADP (sodium salt) Chemical Structure
  58. GC33045 NAMI-A NAMI-A is a ruthenium-based drug characterised by the selective activity against tumour metastases, inhibits the adhesion and migration. NAMI-A Chemical Structure
  59. GC33022 Naquotinib (ASP8273)

    ASP8273

     Naquotinib (ASP8273) (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR. Naquotinib (ASP8273) Chemical Structure
  60. GC32836 Naquotinib mesylate (ASP8273)

    ASP8273 (mesylate)

     Naquotinib mesylate (ASP8273) (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR. Naquotinib mesylate (ASP8273) Chemical Structure
  61. GC36699 Nazartinib mesylate

    EGF816 mesylate

     Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min?1 on EGFR(L858R/790M) mutant, respectively. Nazartinib mesylate Chemical Structure
  62. GC40623 NBI 31772 NBI 31772 is a nonpeptide ligand that releases insulin-like growth factor-1 (IGF-1) from its binding protein (IGFBP; Kis = 1-24 nM for the six human subtypes of IGFBP). NBI 31772 Chemical Structure
  63. GC61111 NBI-31772 hydrate NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate Chemical Structure
  64. GC10644 Neoruscogenin

    25(27)-Dehydroruscogenin

     nuclear receptor RORα agonist Neoruscogenin Chemical Structure
  65. GC10362 Neratinib (HKI-272)

    HKI-272;HKI272;HKI 272

     Neratinib (HKI-272) (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively. Neratinib (HKI-272) Chemical Structure
  66. GC47771 NG 25 (hydrochloride hydrate) An inhibitor of MAP4K2 and TAK1 NG 25 (hydrochloride hydrate) Chemical Structure
  67. GC60270 Nilotinib D6 An internal standard for the quantification of nilotinib Nilotinib D6 Chemical Structure
  68. GC25669 Nilotinib hydrochloride

    AMN-107 HCl

     Nilotinib hydrochloride (AMN-107) is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Nilotinib hydrochloride Chemical Structure
  69. GC14237 Nilotinib monohydrochloride monohydrate A Bcr-Abl inhibitor Nilotinib monohydrochloride monohydrate Chemical Structure
  70. GC14129 Nilotinib(AMN-107)

    AMN107

     A Bcr-Abl inhibitor Nilotinib(AMN-107) Chemical Structure
  71. GC62601 Nimotuzumab Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor drug, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). Nimotuzumab Chemical Structure
  72. GC18211 Ningetinib A multi-kinase inhibitor Ningetinib Chemical Structure
  73. GC36744 Ningetinib Tosylate Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib Tosylate Chemical Structure
  74. GC11705 Nintedanib (BIBF 1120)

    Vargatef

     A VEGFR, FGFR, and PDGFR inhibitor Nintedanib (BIBF 1120) Chemical Structure
  75. GC36745 Nintedanib esylate

    Nintedanib

     Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability (~ 4.7%). Nintedanib esylate Chemical Structure
  76. GN10325 Nobiletin

    NSC 76751, NSC 618903

     Nobiletin Chemical Structure
  77. GC14075 Nocodazole

    NSC 238159, Oncodazole, R 17934

     Nocodazole is an anti-mitotic drug and a rapid and reversible microtubule polymerization inhibitor. It inhibits Abl, Abl (E255K), and Abl (T315I) in cell-free assays with IC50 values of 0.21μM, 0.53μM, and 0.64μM, respectively. Nocodazole Chemical Structure
  78. GC50152 Norleual

    Highly potent HGF/c-MET inhibitor; also AT4 antagonist

     Norleual Chemical Structure
  79. GC69584 Norleual TFA

    Norleual TFA is a type IV angiotensin (Ang) similar substance and a hepatocyte growth factor (HGF)/c-Met inhibitor with an IC50 of 3 pM. It is also an AT4 antagonist with strong anti-angiogenic activity.

     Norleual TFA Chemical Structure
  80. GC14488 NPS-1034 MET inhibitor NPS-1034 Chemical Structure
  81. GC33131 NRC-2694 NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 Chemical Structure
  82. GC14103 NSC228155 EGFR activator NSC228155 Chemical Structure
  83. GC69596 NSC689857

    NSC689857 is an effective inhibitor of EGFR and SCFSKP2, with an IC50 of 36 μM against Skp2-Cks1. NSC689857 can inhibit phosphorylation of p27 (IC50=30 μM). NSC689857 exhibits varying activity in different types of cancer, with higher resistance activity against leukemia cell lines compared to other cancer cells.

     NSC689857 Chemical Structure
  84. GC12712 NT157 IRS-1/2 inhibitor, inhibits IGF-1R and STAT3 signaling pathway NT157 Chemical Structure
  85. GC69599 NT219

    NT219 is an effective dual inhibitor of insulin receptor substrate 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling pathways regulated by various oncogenes. NT219 affects the degradation of IRS1/2 and inhibits the phosphorylation of STAT3. NT219 has potential for researching cancer diseases.

     NT219 Chemical Structure
  86. GC10720 NTR 368 cytoplasmic peptide of the neurotrophin receptor p75NTR NTR 368 Chemical Structure
  87. GC34126 NVP-ACC789 (ACC-789) NVP-ACC789 (ACC-789) is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively. NVP-ACC789 (ACC-789) Chemical Structure
  88. GC14310 NVP-ADW742

    ADW742, GSK552602A

     Selective IGF-1R inhibitor NVP-ADW742 Chemical Structure
  89. GC12963 NVP-AEW541

    AEW541

     IGF-IR inhibitor, novel, potent and selective NVP-AEW541 Chemical Structure
  90. GC16028 NVP-BGJ398 phosphate NVP-BGJ398 phosphate Chemical Structure
  91. GC14332 NVP-BHG712 EphB4 inhibitor,potent and selective NVP-BHG712 Chemical Structure
  92. GC36782 NVP-BHG712 isomer NVP-BHG712 isomer, a regioisomer of NVP-BHG712, shows conserved non-bonded binding to EPHA2 and EPHB4. NVP-BHG712 isomer Chemical Structure
  93. GC16972 NVP-BVU972 C-Met inhibitor,potent and selective NVP-BVU972 Chemical Structure
  94. GC44491 O-Desmethyl Gefitinib O-Desmethyl gefitinib is the major metabolite of gefitinib in human plasma, formed by the cytochrome P450 isoform CYP2D6. O-Desmethyl Gefitinib Chemical Structure
  95. GC68321 O-Desmethyl gefitinib-d8 O-Desmethyl gefitinib-d8 Chemical Structure
  96. GC64950 ODM-203 ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment. ODM-203 Chemical Structure
  97. GC32502 Oglufanide (H-Glu-Trp-OH) Oglufanide (H-Glu-Trp-OH) (H-Glu-Trp-OH) is a dipeptide immunomodulator isolated from calf thymus. Oglufanide (H-Glu-Trp-OH) Chemical Structure
  98. GC69619 Olaratumab

    IMC-3G3; LY3012207

    Olaratumab (IMC-3G3; LY3012207) is a human monoclonal IgG1 antibody that targets platelet-derived growth factor receptor alpha (PDGFRα) and has anti-tumor activity.

     Olaratumab Chemical Structure
  99. GC15370 Olmutinib (HM61713, BI 1482694)

    BI-1482694, Olmutinib

     Olmutinib (HM61713, BI 1482694) (HM61713; BI-1482694) is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib (HM61713, BI 1482694) is used for NSCLC. Olmutinib (HM61713, BI 1482694) Chemical Structure
  100. GC62207 Olverembatinib

    GZD824; HQP1351

     Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity. Olverembatinib Chemical Structure
  101. GC36807 ON 146040 ON 146040 is a potent PI3Kα and PI3Kδ (IC50≈14 and 20 nM, respectively) inhibitor. ON 146040 also inhibits Abl1 (IC50<150 nM). ON 146040 Chemical Structure

Items 701 to 800 of 1198 total

per page
  2. 6
  3. 7
  4. 8
  5. 9
  6. 10

Set Descending Direction